Bicycle Therapeutics (BCYC) Stock Forecast, Price & News

Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

Is Bicycle Therapeutics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics or view top-rated stocks.

Are investors shorting Bicycle Therapeutics?

Bicycle Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,470,000 shares, an increase of 27.3% from the April 30th total of 1,940,000 shares. Based on an average daily trading volume, of 572,500 shares, the days-to-cover ratio is currently 4.3 days.
View Bicycle Therapeutics' Short Interest.

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Bicycle Therapeutics.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) released its quarterly earnings results on Thursday, May, 5th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.23. The firm earned $3.86 million during the quarter, compared to the consensus estimate of $3.46 million. Bicycle Therapeutics had a negative net margin of 568.71% and a negative trailing twelve-month return on equity of 31.61%.
View Bicycle Therapeutics' earnings history.

What price target have analysts set for BCYC?

10 Wall Street analysts have issued 12 month target prices for Bicycle Therapeutics' shares. Their forecasts range from $33.00 to $80.00. On average, they anticipate Bicycle Therapeutics' stock price to reach $62.00 in the next twelve months. This suggests a possible upside of 289.2% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the following people:

• Dr. Kevin Lee M.B.A., Ph.D., CEO & Exec. Director (Age 53, Pay $1.16M)
• Mr. Lee H. Kalowski M.B.A., MBA, Pres & CFO (Age 41, Pay $756.13k)
• Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 71, Pay $40k)
• Dr. Michael Skynner B.sc. Ph.d., Ph.D., Chief Technology Officer (Age 52, Pay $769.01k)
• Dr. Nigel Crockett Ph.D., Chief Bus. Officer (Age 57, Pay $568.12k)
• Dr. Dominic Smethurst M.A., M.D., Chief Medical Officer (Age 48, Pay $431.7k)
• Dr. Christian Heinis, Scientific Founder
• Mr. Alistair Milnes, Chief Operating Officer
• Dr. Nicholas Keen Ph.D., Chief Scientific Officer (Age 54)
• Mr. David E. Borah CFA, VP of Capital Markets & Investor Relations

Who are some of Bicycle Therapeutics' key competitors?

Some companies that are related to Bicycle Therapeutics include Schrödinger (SDGR), Turning Point Therapeutics (TPTX), Emergent BioSolutions (EBS), Ironwood Pharmaceuticals (IRWD), Global Blood Therapeutics (GBT), Aurinia Pharmaceuticals (AUPH), ChemoCentryx (CCXI), HUTCHMED (HCM), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Xenon Pharmaceuticals (XENE), Arcus Biosciences (RCUS) and Taro Pharmaceutical Industries (TARO).
View all of BCYC's competitors.

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Deep Track Capital LP (6.26%), RTW Investments LP (4.30%), Tybourne Capital Management HK Ltd. (3.89%), SV Health Investors LLC (3.09%), First Light Asset Management LLC (3.00%) and Loomis Sayles & Co. L P (2.17%). Company insiders that own Bicycle Therapeutics stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends for Bicycle Therapeutics.

Which institutional investors are selling Bicycle Therapeutics stock?

BCYC stock was sold by a variety of institutional investors in the last quarter, including Tybourne Capital Management HK Ltd., Acadian Asset Management LLC, First Light Asset Management LLC, Verition Fund Management LLC, Bellevue Group AG, Victory Capital Management Inc., BlackRock Inc., and Renaissance Technologies LLC. Company insiders that have sold Bicycle Therapeutics company stock in the last year include Kate Bingham, Kevin Lee, Lee Kalowski, Nigel Crockett, Pierre Legault, and Stephen B Alexander.
View insider buying and selling activity for Bicycle Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Bicycle Therapeutics stock?

BCYC stock was acquired by a variety of institutional investors in the last quarter, including Deep Track Capital LP, Frazier Life Sciences Management L.P., RTW Investments LP, Great Point Partners LLC, Goldman Sachs Group Inc., Ghost Tree Capital LLC, Loomis Sayles & Co. L P, and Handelsbanken Fonder AB.
View insider buying and selling activity for Bicycle Therapeutics or or view top insider-buying stocks.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $15.93.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics has a market capitalization of $472.32 million and generates $11.70 million in revenue each year. The company earns $-66.82 million in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

Bicycle Therapeutics employs 119 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 441223261503.